242 related articles for article (PubMed ID: 21796104)
21. Benzodiazepines have no effect on fear-potentiated startle in humans.
Baas JM; Grillon C; Böcker KB; Brack AA; Morgan CA; Kenemans JL; Verbaten MN
Psychopharmacology (Berl); 2002 May; 161(3):233-47. PubMed ID: 12021826
[TBL] [Abstract][Full Text] [Related]
22. Validating a human model for anxiety using startle potentiated by cue and context: the effects of alprazolam, pregabalin, and diphenhydramine.
Baas JM; Mol N; Kenemans JL; Prinssen EP; Niklson I; Xia-Chen C; Broeyer F; van Gerven J
Psychopharmacology (Berl); 2009 Jul; 205(1):73-84. PubMed ID: 19415242
[TBL] [Abstract][Full Text] [Related]
23. Diazepam and flurazepam: effects on conditioned fear as measured with the potentiated startle paradigm.
Davis M
Psychopharmacology (Berl); 1979 Mar; 62(1):1-7. PubMed ID: 35808
[TBL] [Abstract][Full Text] [Related]
24. Lesions of the central gray block conditioned fear as measured with the potentiated startle paradigm.
Fendt M; Koch M; Schnitzler HU
Behav Brain Res; 1996 Jan; 74(1-2):127-34. PubMed ID: 8851921
[TBL] [Abstract][Full Text] [Related]
25. Morphine and naloxone: effects on conditioned fear as measured with the potentiated startle paradigm.
Davis M
Eur J Pharmacol; 1979 Mar; 54(4):341-7. PubMed ID: 436933
[TBL] [Abstract][Full Text] [Related]
26. Pharmacological and anatomical analysis of fear conditioning using the fear-potentiated startle paradigm.
Davis M
Behav Neurosci; 1986 Dec; 100(6):814-24. PubMed ID: 3545257
[TBL] [Abstract][Full Text] [Related]
27. Acoustic startle and fear-potentiated startle in alcohol-preferring (P) and -nonpreferring (NP) lines of rats.
Mckinzie DL; Sajdyk TJ; Mcbride WJ; Murphy JM; Lumeng L; Li TK; Shekhar A
Pharmacol Biochem Behav; 2000 Apr; 65(4):691-6. PubMed ID: 10764924
[TBL] [Abstract][Full Text] [Related]
28. Differential effects of the CRF-R1 antagonist GSK876008 on fear-potentiated, light- and CRF-enhanced startle suggest preferential involvement in sustained vs phasic threat responses.
Walker D; Yang Y; Ratti E; Corsi M; Trist D; Davis M
Neuropsychopharmacology; 2009 May; 34(6):1533-42. PubMed ID: 19078950
[TBL] [Abstract][Full Text] [Related]
29. Light-enhanced and fear-potentiated startle: temporal characteristics and effects of alpha-helical corticotropin-releasing hormone.
de Jongh R; Groenink L; van der Gugten J; Olivier B
Biol Psychiatry; 2003 Nov; 54(10):1041-8. PubMed ID: 14625146
[TBL] [Abstract][Full Text] [Related]
30. Anxiogenic-like effects of opiate withdrawal seen in the fear-potentiated startle test, an interdisciplinary probe for drug-related motivational states.
Fendt M; Mucha RF
Psychopharmacology (Berl); 2001 May; 155(3):242-50. PubMed ID: 11432686
[TBL] [Abstract][Full Text] [Related]
31. The effect of intranasal oxytocin treatment on conditioned fear extinction and recall in a healthy human sample.
Acheson D; Feifel D; de Wilde S; McKinney R; Lohr J; Risbrough V
Psychopharmacology (Berl); 2013 Sep; 229(1):199-208. PubMed ID: 23644911
[TBL] [Abstract][Full Text] [Related]
32. The role of neuropeptide Y in the expression and extinction of fear-potentiated startle.
Gutman AR; Yang Y; Ressler KJ; Davis M
J Neurosci; 2008 Nov; 28(48):12682-90. PubMed ID: 19036961
[TBL] [Abstract][Full Text] [Related]
33. Control conditions in the fear-potentiated startle response paradigm.
Joordens RJ; Hijzen TH; Peeters BW; Olivier B
Neuroreport; 1997 Mar; 8(4):1031-4. PubMed ID: 9141086
[TBL] [Abstract][Full Text] [Related]
34. Acute escitalopram but not contextual conditioning exerts a stronger "anxiogenic" effect in rats with high baseline "anxiety" in the acoustic startle paradigm.
Pettersson R; Näslund J; Nilsson S; Eriksson E; Hagsäter SM
Psychopharmacology (Berl); 2015 Apr; 232(8):1461-9. PubMed ID: 25417552
[TBL] [Abstract][Full Text] [Related]
35. Involvement of subcortical and cortical afferents to the lateral nucleus of the amygdala in fear conditioning measured with fear-potentiated startle in rats trained concurrently with auditory and visual conditioned stimuli.
Campeau S; Davis M
J Neurosci; 1995 Mar; 15(3 Pt 2):2312-27. PubMed ID: 7891169
[TBL] [Abstract][Full Text] [Related]
36. Anxiolytic effects of buspirone and gepirone in the fear-potentiated startle paradigm.
Kehne JH; Cassella JV; Davis M
Psychopharmacology (Berl); 1988; 94(1):8-13. PubMed ID: 2894703
[TBL] [Abstract][Full Text] [Related]
37. Progesterone attenuates corticotropin-releasing factor-enhanced but not fear-potentiated startle via the activity of its neuroactive metabolite, allopregnanolone.
Toufexis DJ; Davis C; Hammond A; Davis M
J Neurosci; 2004 Nov; 24(45):10280-7. PubMed ID: 15537900
[TBL] [Abstract][Full Text] [Related]
38. Phasic and sustained fear are pharmacologically dissociable in rats.
Miles L; Davis M; Walker D
Neuropsychopharmacology; 2011 Jul; 36(8):1563-74. PubMed ID: 21471958
[TBL] [Abstract][Full Text] [Related]
39. The brain orexin system and almorexant in fear-conditioned startle reactions in the rat.
Steiner MA; Lecourt H; Jenck F
Psychopharmacology (Berl); 2012 Oct; 223(4):465-75. PubMed ID: 22592903
[TBL] [Abstract][Full Text] [Related]
40. The nonhuman primate amygdala is necessary for the acquisition but not the retention of fear-potentiated startle.
Antoniadis EA; Winslow JT; Davis M; Amaral DG
Biol Psychiatry; 2009 Feb; 65(3):241-8. PubMed ID: 18823878
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
